MedTrace Logo

Combined Basal-bolus Insulin and Post-exercise Carbohydrate Feeding Strategy in T1DM

NCT02204839 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2015-01-15

No results posted yet for this study

Summary

The investigators hypothesise that reducing basal insulin dose (Glargine, Lantus, Sanofi-Aventis, or Detemir, Levemir, Novo Nordisk), whilst employing current carbohydrate feeding and rapid-acting insulin dose recommendations will protect patients with type 1 diabetes from early- and late-onset hypoglycaemia following evening time exercise.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

DRUG

Basal insulin dose

Sponsors & Collaborators

  • Newcastle University

    collaborator OTHER

  • Northumbria University

    lead OTHER

Principal Investigators

  • Daniel J West, PhD · Northumbria University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02204839 on ClinicalTrials.gov